Comment le ratio PB de MESO se compare-t-il à celui de ses pairs ?

MESO offre un bon rapport qualité-prix en fonction de son ratio Price-To-Book ( 2.5 x) par rapport à la moyenne des pairs ( 3.1 x).

Comment le ratio PB de MESO se compare-t-il à celui d'autres entreprises du secteur US Biotechs ?

MESO est cher en fonction de son ratio Price-To-Book ( 2.5 x) par rapport à la moyenne du secteur US Biotechs ( 1.8 x).

Quel est le ratio PB de MESO par rapport à son ratio équitable PB? Il s'agit du ratio PB attendu, compte tenu des prévisions de croissance des bénéfices de l'entreprise, des marges bénéficiaires et d'autres facteurs de risque.

Données insuffisantes pour calculer le ratio d'équité { Price-To-Book MESO } pour l'analyse de valorisation.

Quel est le juste prix de MESO si l'on considère ses flux de trésorerie futurs ? Pour cette estimation, nous utilisons un modèle d'actualisation des flux de trésorerie.

MESO ( $10.82 ) se négocie en dessous de notre estimation de la [[juste valeur]] ( $167.14 )

Quelles sont les prévisions à 12 mois des analystes et avons-nous une confiance statistique dans l'objectif de prix du consensus ?

Données insuffisantes pour afficher les prévisions de prix.

Mesoblast (Nasdaq:MESO) - Cours de l'action, nouvelles et analyse

MESO Aperçu des actions

Mesoblast Limited développe des produits de médecine régénérative en Australie, aux États-Unis, à Singapour et en Suisse. Plus de détails

MESO analyse fondamentale
Score flocon de neige
Évaluation	3/6
Croissance future	5/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Récompenses

Se négocie à 93.5% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 61.47% par an

Analyse des risques

Les actionnaires ont été dilués au cours de l'année écoulée

Volatilité du cours de l'action au cours des 3 derniers mois

Mesoblast Limited Concurrents

Gracell Biotechnologies

NasdaqGS:GRCL

US$990.8m

Arcus Biosciences

NYSE:RCUS

US$1.3b

CareDx

NasdaqGM:CDNA

US$1.2b

Prothena

NasdaqGS:PRTA

US$756.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Mesoblast
Historique des cours de bourse
Prix actuel de l'action	AU$10.82
Plus haut sur 52 semaines	AU$12.18
Plus bas sur 52 semaines	AU$1.61
Bêta	2.34
1Variation sur 1 mois	12.12%
Variation sur 3 mois	68.27%
Variation sur 1 an	303.73%
3Variation sur 3 ans	-15.20%
Variation sur 5 ans	-14.80%
Évolution depuis l'introduction en bourse	32.73%

Nouvelles et mises à jour récentes

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30

Mesoblast: Rolling The Dice On Cellular Medicines

Jul 22

Recent updates

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Apr 30

Mesoblast issues FQ2 operational and financial update

Jan 29

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Jan 11

Mesoblast: The Future Looks Bleak

Dec 24

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Dec 15

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Dec 02

Mesoblast EPS beats by $0.22, misses on revenue

Nov 19

Rendement pour les actionnaires

	MESO	US Biotechs	US Marché
7D	-7.6%	-7.5%	-1.2%
1Y	303.7%	14.1%	30.4%

Rendement vs Industrie: MESO a dépassé le secteur US Biotechs qui a rapporté 14.1 % au cours de l'année écoulée.

Rendement vs marché: MESO a dépassé le marché US qui a rapporté 30.4 % au cours de l'année écoulée.

Volatilité des prix

Is MESO's price volatile compared to industry and market?
MESO volatility
MESO Average Weekly Movement	11.1%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de MESO a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de MESO a diminué de 17% à 11% au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2004	73	Silviu Itescu	www.mesoblast.com

Mesoblast Limited développe des produits de médecine régénérative en Australie, aux États-Unis, à Singapour et en Suisse. Sa plateforme technologique propriétaire de médecine régénérative est basée sur des cellules spécialisées connues sous le nom de cellules de la lignée mésenchymateuse. La société propose Remestemcel-L, qui fait l'objet d'essais cliniques de phase III pour le traitement des maladies inflammatoires systémiques, notamment la maladie aiguë du greffon contre l'hôte réfractaire aux stéroïdes et la maladie inflammatoire de l'intestin réfractaire aux produits biologiques, ainsi que la maladie de Crohn ; et Remestemcel-L, qui fait l'objet d'essais cliniques de phase III pour le traitement de l'insuffisance cardiaque chronique et de la lombalgie chronique due à la discopathie dégénérative.

Mesoblast Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de Mesoblast se comparent-ils à sa capitalisation boursière ?
MESO statistiques fondamentales
Capitalisation boursière	US$1.20b
Bénéfices(TTM)	-US$87.96m
Recettes(TTM)	US$5.90m

202.7x

Ratio P/S

-13.6x

Ratio P/E

Le site MESO est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
MESO compte de résultat (TTM)
Recettes	US$5.90m
Coût des recettes	US$41.07m
Marge brute	-US$35.17m
Autres dépenses	US$52.79m
Les revenus	-US$87.96m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.077
Marge brute	-595.87%
Marge bénéficiaire nette	-1,490.27%
Ratio dettes/capitaux propres	23.8%

Quelles ont été les performances à long terme de MESO?

Voir les performances historiques et les comparaisons

MESO Aperçu des actions

Récompenses

Analyse des risques

Mesoblast Limited Concurrents

NasdaqGS:GRCL

US$990.8m

NYSE:RCUS

US$1.3b

NasdaqGM:CDNA

US$1.2b

NasdaqGS:PRTA

US$756.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Mesoblast Limited: Back From The Dead

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast issues FQ2 operational and financial update

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Mesoblast: The Future Looks Bleak

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L